Leica Microsystems and Epitomics Enter Agreement for Supply of Proprietary Rabbit Monoclonal Antibodies

NEWCASTLE-UPON-TYNE, England, February 29, 2012 /PRNewswire/ –

Leica Microsystems and Epitomics, Inc. announced today that they had reached an
agreement for the supply of proprietary rabbit monoclonal antibodies to Leica
Microsystems, based on Epitomics, RabMAb(R) technology. The agreement also provides
long-term support for Leica’s incorporation of Epitomics’ products into higher regulatory
classifications of IVD products.

“We are very pleased to enter into this strategic relationship with Epitomics”
comments Dr. Konstantin Fiedler, Vice President of Advanced Staining for Leica’s
Biosystems Division. “In December we released the first one-step double staining detection
system, Leica ChromoPlex 1(TM) Dual Detection for BOND. Our agreement with Epitomics will
allow us to build a supporting range of antibody cocktails based of the leading
Novocastra(TM) mouse monoclonal antibodies and Epitomics RabMAb(R) rabbit monoclonal
antibodies. Additionally, with a selection of Epitomics’ rabbit monoclonal antibodies we
will also be able to further strengthen our portfolio of Novocastra concentrated and Bond
Ready-to-Use antibody selection for our BOND instruments.”

“We are very pleased to see our RabMabs are incorporated into one of the most advanced
automated immunohistochemistry (IHC) staining systems for pathology laboratories in the
world. This agreement is another important endorsement of the quality of Epitomics
products in the rapidly growing field of IHC for anatomic pathology. Epitomics has
accumulated a collection of candidate antibodies for potential future incorporation into
companion diagnostics products in recent years. This strategic relationship will take us
to the next level.” says Dr. Guo-Liang Yu, President and CEO of Epitomics Inc.

About Leica Microsystems

Leica Microsystems is a world leader in microscopes and scientific instruments.
Founded as a family business in the nineteenth century, the company’s history was marked
by unparalleled innovation on its way to becoming a global enterprise.

Its historically close cooperation with the scientific community is the key to Leica
Microsystems’ tradition of innovation, which draws on users’ ideas and creates solutions
tailored to their requirements. At the global level, Leica Microsystems is organized in
four divisions, all of which are among the leaders in their respective fields: the Life
Science Division, Industry Division, Biosystems Division and Medical Division.

Leica Microsystems’ Biosystems Division, also known as Leica Biosystems, offers
histopathology laboratories the most extensive product range with appropriate products for
each work step in histology and for a high level of productivity in the working processes
of the entire laboratory.

The company is represented in over 100 countries with 12 manufacturing facilities in 7
countries, sales and service organizations in 19 countries and an international network of
dealers. The company is headquartered in Wetzlar, Germany.

About Epitomics

Epitomics, Inc., an emerging biotechnology company, is dedicated to developing
breakthrough monoclonal antibody technology for research, diagnostic and therapeutic
applications. The Company utilizes a unique and proprietary RabMAb(R) (Rabbit Monoclonal
Antibody) technology which produces antibodies with superior binding affinity and
bioactivity in a wide variety of biological assays. Epitomics, Inc. is headquartered in
Burlingame, California, and operates a wholly owned subsidiary in Hangzhou, the People’s
Republic of China.

http://www.epitomics.com

        For further information, please contact:
        DeanHutchinson
        MarketingCommunicationsManager
        Leica Biosystems Ltd
        Balliol Business Park West
        Benton Lane
        Newcastle upon Tyne
        NE12 8EW
        Telephone: +44-191-215-0567
        Fax: +44-191-215-1152
        Mobile: +44-7919-33-29-13
        Direct Line: +44-191-215-4205

SOURCE Leica Microsystems